Business Context and Reporting Period
This Form 8-K is a current report filed by Sonus Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata) on December 14, 2005. The filing discloses the entry into a material definitive agreement regarding changes to the compensation structure for non-employee members of the Board of Directors, effective January 1, 2006.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the specific terms of the new director compensation agreement.
Material Changes Versus Prior Period
The Board of Directors approved the following increases to non-employee director compensation effective January 1, 2006:
- Annual Retainer: Increased by $9,000 to a total of $24,000, paid quarterly.
- Meeting Fees: Increased by $250 per meeting. In-person meetings are now $1,250, and telephonic meetings are $750.
- Committee Fees: Committee members will receive $500 per committee meeting.
- Chairman Retainers: New annual retainers established for the Chairman of the Audit Committee ($3,000) and the Chairman of the Board ($2,000), both paid quarterly. Previously, these roles received no additional compensation.
- Stock Options:
- Current non-employee directors: Annual option grant increased by 7,000 shares to 17,000 shares.
- New directors: Expected to receive an option grant of 22,500 shares (an increase of 7,500 shares).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies beyond the implementation of the new compensation terms. No unusual items were reported.
Investor Verification Checklist
- Verify the exact effective date of the compensation changes (January 1, 2006).
- Confirm the total number of non-employee directors to calculate the aggregate impact on cash compensation and potential dilution from stock options.
- Review the company's most recent 10-K or 10-Q to assess the impact of increased director compensation on overall operating expenses.
- Check the stock option grant terms (exercise price, vesting schedule) which are not detailed in this 8-K.